CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its offerings to include a suite of stem cell services. The initiative advances Cellaria’s mission to provide more accurate patient and disease-specific cell models to help researchers focus and accelerate their research and discovery efforts.
Cellaria’s new stem cell division will provide RNA reprogramming and differentiation services in a comprehensive, yet modular workflow. The company’s initial reprogramming focus will be on custom solutions for primary cell establishment, induced pluripotent stem cell (iPSC) generation, banking and characterization. Cellaria will also offer customizable differentiation services for various cell types such as neurons, hepatocytes and skeletal muscle.
By incorporating the most advanced RNA technology, Cellaria’s reprogramming platform will enable access to a broad set of patient cells, including cells derived from human skin and blood, for the development of the next generation of disease models. With the addition of an extremely flexible and tailored differentiation system, Cellaria provides a single source solution to stem cell services.
Human induced pluripotent stem cells (iPSCs) are generated from adult cells and have the ability to self-renew and differentiate into various different cells of the body. Human iPSCs have significantly impacted the scope of regenerative medicine and tools used to interrogate disease pathology. Cellaria’s comprehensive stem cell offerings, combined with over 20 years of in-house experience in RNA-iPS cell biology, will provide models that are easily translatable and impactful to disease research.
“RNA Reprogramming is a valuable and necessary tool for creating disease-specific cell lines for modeling,” said David Deems, chief executive officer at Cellaria. “It is also increasingly being identified as a mechanism of tumor plasticity. We are genuinely excited to add a comprehensive suite of stem cell services and begin exploring the intersection between stem cell and cancer models.”
More information on Cellaria’s stem cell services is available at cellariabio.com/stemcell.
Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patient’s biology. All models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria’s cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation and stem cell services, Cellaria’s cell models enable interrogation of patient and disease-specific mechanisms of action. Cellaria’s innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure. For more information, visit www.cellariabio.com.
CONTACT: Contact: Tim Walsh for Cellaria Bio 617.512.1641 email@example.com